Results 11 to 20 of about 527 (122)

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we
Justin D. Lutz   +5 more
doaj   +3 more sources

Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM).
Donghong Xu   +6 more
doaj   +3 more sources

The Central Role of Echocardiography in Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Comprehensive Review [PDF]

open access: yesCardiology Research and Practice
Mavacamten is a cardiac myosin inhibitor used in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Echocardiography is central to selecting suitable patients, confirming left ventricular outflow tract (LVOT) obstruction, excluding ...
Ali Nizam   +4 more
doaj   +3 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy [PDF]

open access: yesBiomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +3 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy [PDF]

open access: yesThe Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi   +14 more
doaj   +6 more sources

Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system [PDF]

open access: yesFrontiers in Pharmacology
BackgroundTo evaluate the cost-effectiveness of aficamten plus standard of care (SoC) versus SoC alone for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the perspective of the Chinese healthcare system.MethodsA four-state ...
Feng Zhai   +5 more
doaj   +2 more sources

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM [PDF]

open access: yesCirculation
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM) is associated with significant morbidity with no approved treatment.
Felix Jose Alvarez Ramires   +368 more
core   +2 more sources

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population [PDF]

open access: yesDrug Design, Development and Therapy
Ziyang Wang, Xiaofei Wu, Ranran Jia, Hongyun WangClinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China*These
Wang Z, Wu X, Jia R, Wang H
doaj   +2 more sources

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton J. Davis   +13 more
doaj   +2 more sources

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure [PDF]

open access: yesJACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD   +17 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy